On 22 October 2025, Raffles Medical Group (RMG) and Gene Solutions signed a Memorandum of Understanding (MOU) to streamline patient recruitment for oncology clinical trials in Southeast Asia. This partnership aims to connect patients with advanced genomic markers to innovative pharma-sponsored trials.

• Automated Trial Matching: Patients who undergo Comprehensive Genomic Profiling (CGP) via Gene Solutions’ tests will be automatically screened for eligibility in global clinical trials hosted by RMG.
• Signature Technology: The partnership utilizes K-4CARE, a signature test that decodes a tumor’s DNA and RNA profile to identify mutations that qualify patients for targeted therapies or investigational drugs.
• Initial Focus (KRYSTAL-7): The collaboration launches with the KRYSTAL-7 study, which evaluates first-line treatment for non-small cell lung cancer (NSCLC) patients harboring the KRAS G12C mutation.
• Regional Reach: Leveraging Gene Solutions’ significant market share in Vietnam and RMG’s clinical network in Singapore and Indochina, the initiative aims to provide more equitable access to cutting-edge precision medicine across the region.

This summary is based on a press release issued by Gene Solutions.